Beijing Innocare Pharma Tech Co., Ltd.

This study tests an oral medication called ICP-332 for adults with moderate to severe atopic dermatitis (eczema). About 552 participants will receive either the drug or a placebo daily for several weeks. The main goal is to see if the drug significantly reduces skin redness, itch…

This study tests a new drug, ICP-248, combined with orelabrutinib in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if the combination is safe and helps control the disease. About 226 adults aged 18 to 80 will take part. This …

This early-stage study tests a new drug called ICP-248, alone or with another drug, in adults with certain blood cancers (B-cell malignancies). The main goals are to check safety, find the best dose, and see if it helps shrink tumors. About 191 people will take part.

This study tests an experimental drug called ICP-723 in adults and teenagers with advanced solid tumors that cannot be removed by surgery. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 310 participants will take part i…

This study tests an experimental drug called ICP-248 in 75 adults whose mantle cell lymphoma has returned or stopped responding to prior therapy. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also monitor side effects and how long any ben…

This study tests whether a new combination of drugs (orelabrutinib plus rituximab) works better than another standard combo (lenalidomide plus rituximab) for people with marginal zone lymphoma that has returned or stopped responding to prior therapy. About 324 adults who have alr…

This study tests an oral medication called ICP-488 for adults with moderate to severe plaque psoriasis. About 383 participants will receive either the drug or a placebo to see if it safely clears skin and reduces symptoms. The main goal is to measure skin improvement after 16 wee…

This study tests an experimental drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. The main goal is to see if more people achieve a 75% improvement in their psoriasis symptoms after 12 weeks of treatment. Participants must have had psor…

This study tests an experimental drug called ICP-723 in people whose advanced solid tumors or brain tumors have a specific genetic change called NTRK fusion. About 70 participants will receive the drug to see if it shrinks tumors or slows their growth. The goal is to find a new t…

This early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…

This study tests an experimental drug called ICP-332 for people with prurigo nodularis, a skin condition causing many intensely itchy bumps. About 135 adults will receive either the drug or a placebo to see if it reduces itching and clears the bumps over 16 weeks. The goal is to …

This study tests an experimental drug called ICP-332 for people with moderate to severe chronic hives (chronic spontaneous urticaria) that don't get better with standard antihistamines. The goal is to see if the drug reduces itching and welts better than a placebo. About 344 adul…

This early-stage study tests whether the experimental drug ICP-538 is safe in healthy adults. About 104 participants will receive either the drug or a placebo. The study measures side effects and how the body processes the drug, but does not aim to treat any disease.